119 results
6-K
EX-1
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
to patients and to maximize the value of this innovative therapeutic candidate.
The FDA approval of APHEXDA is based on results from the 2-part, Phase … for, and commercialize products for a second OTC indication. In turn, in March 2020, we agreed with our licensor of the rights to BL-5010, Innovative Pharmaceutical
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life
6-K
EX-99
BLRX
Bioline Rx Ltd
24 May 24
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial
7:05am
, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life
6-K
EX-99
BLRX
Bioline Rx Ltd
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative
6-K
EX-99
3mughzgrzf7wi7yc
6 May 24
Current report (foreign)
7:14am
6-K
EX-99.1
e9q8ssku
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
6-K
EX-99
hzuovub rfj
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
6-K
EX-99.1
62s 1dtcts6wdvy
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
0y2vcpu
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
n397nyf3r9nnief6r 1y
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
jbv21d 6awxfnwv
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
u6594m0bl4huyo8jtk
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
faxc09 o5is0bfg7
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
2exr5kk5
16 Feb 24
Current report (foreign)
7:07am
6-K
EX-99
0vr023iqnl8dlq11dm
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
w13tkhsyban g40ouze7
12 Dec 23
Current report (foreign)
7:07am
6-K
EX-99
wonx31jt
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
urh39ib4 tb44z1mh
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am